Naringenin attenuates pressure overload-induced cardiac hypertrophy

Zhang,Ning; Yang,Zheng; Yuan,Yuan; Li,Fangfang; Liu,Yuan; Ma,Zhenguo; Liao,Haihan; Bian,Zhouyan; Zhang,Yao; Zhou,Heng; Deng,Wei; Zhou,Mengqiao; Tang,Qizhu

doi:10.3892/etm.2015.2816

Naringenin attenuates pressure overload-induced cardiac hypertrophy

Authors:
- Ning Zhang
- Zheng Yang
- Yuan Yuan
- Fangfang Li
- Yuan Liu
- Zhenguo Ma
- Haihan Liao
- Zhouyan Bian
- Yao Zhang
- Heng Zhou
- Wei Deng
- Mengqiao Zhou
- Qizhu Tang
View Affiliations

Affiliations: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: October 19, 2015 https://doi.org/10.3892/etm.2015.2816
Pages: 2206-2212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac hypertrophy is characterized by abnormal enlargement of cardiomyocytes and disproportionate accumulation of extracellular interstitial fibrosis, which are major predictors of the development of coronary artery disease and heart failure. Naringenin is a bitter principle component of grapefruit that has numerous pharmacological effects, including anti‑inflammatory, hypolipidemic, antithrombotic and antiatherogenic properties. In order to investigate whether naringenin is able to exert a protective effect against cardiac hypertrophy induced by pressure overload, aortic banding (AB) was performed to induce cardiac hypertrophy in mice, and naringenin was administered for 7 weeks. A total of 60 mice were allocated into four groups: Sham + vehicle, AB + vehicle, sham + naringenin and AB + naringenin. Naringenin treatment attenuated cardiac dysfunction, as indicated by the results of echocardiography and catheter‑based measurements at 8 weeks post‑surgery. The extent of cardiac hypertrophy was assessed by the heart weight/body weight, heart weight/tibial length and lung weight/body weight ratios, in addition to the cardiomyocyte cross‑sectional area and the mRNA expression levels of hypertrophic maker, all of which were mitigated by naringenin administration. Naringenin also inhibited the expression of transforming growth factor‑β1, connective tissue growth factor, collagen Iα and collagen IIIα, and attenuated interstitial fibrosis. In addition, naringenin downregulated the activation of the extracellular signal‑regulated kinase (ERK), c‑Jun N‑terminal kinase (JNK) and phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt) signaling pathways. In conclusion, naringenin attenuated cardiac hypertrophy and interstitial fibrosis, in addition to improving left ventricular function in pressure‑overloaded mice. The cardioprotective effect exerted by naringenin may be associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways.

View Figures

View References

1	Balakumar P and Jagadeesh G: Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared? Pharmacol Res. 62:365–383. 2010. View Article : Google Scholar : PubMed/NCBI
2	Gjesdal O, Bluemke DA and Lima JA: Cardiac remodeling at the population level-risk factors, screening and outcomes. Nat Rev Cardiol. 8:673–685. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hellawell JL and Margulies KB: Myocardial reverse remodeling. Cardiovasc Ther. 30:172–181. 2012. View Article : Google Scholar : PubMed/NCBI
4	van Berlo JH, Maillet M and Molkentin JD: Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 123:37–45. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, Gan HW, Yang Z, Li H and Tang QZ: Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol. 63:73–81. 2014. View Article : Google Scholar : PubMed/NCBI
6	Middleton E Jr and Kandaswami C: Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol. 43:1167–1169. 1992. View Article : Google Scholar : PubMed/NCBI
7	Oshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Colditz G, Ascherio A, Rosner B, Spiegelman D and Willett WC: The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 134:1106–1114. 2001. View Article : Google Scholar : PubMed/NCBI
8	Dauchet L, Ferrières J, Arveiler D, Yarnell JW, Gey F, Ducimetière P, Ruidavets JB, Haas B, Evans A, Bingham A, et al: Frequency of fruit and vegetable consumption and coronary heart disease in France and Northern Ireland: The PRIME study. Br J Nutr. 92:963–972. 2004. View Article : Google Scholar : PubMed/NCBI
9	Saponara S, Testai L, Iozzi D, Martinotti E, Martelli A, Chericoni S, Sgaragli G, Fusi F and Calderone V: (+/−)-Naringenin as large conductance Ca(2+)-activated K+ (BKCa) channel opener in vascular smooth muscle cells. Br J Pharmacol. 149:1013–1021. 2006. View Article : Google Scholar : PubMed/NCBI
10	Testai L, Martelli A, Marino A, D'Antongiovanni V, Ciregia F, Giusti L, Lucacchini A, Chericoni S, Breschi MC and Calderone V: The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury. Biochem Pharmacol. 85:1634–1643. 2013. View Article : Google Scholar : PubMed/NCBI
11	Yan L, Huang H, Tang QZ, Zhu LH, Wang L, Liu C, Bian ZY and Li H: Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem. 109:1158–1171. 2010.PubMed/NCBI
12	Zhou H, Bian ZY, Zong J, Deng W, Yan L, Shen DF, Guo H, Dai J, Yuan Y, Zhang R, et al: Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension. 60:802–809. 2012. View Article : Google Scholar : PubMed/NCBI
13	Carreño JE, Apablaza F, Ocaranza MP and Jalil JE: Cardiac hypertrophy: Molecular and cellular events. Rev Esp Cardiol. 59:473–486. 2006.(In Spanish). View Article : Google Scholar : PubMed/NCBI
14	Frey N and Olson EN: Cardiac hypertrophy: The good, the bad and the ugly. Annu Rev Physiol. 65:45–79. 2003. View Article : Google Scholar : PubMed/NCBI
15	Lorenz K, Schmitt JP, Vidal M and Lohse MJ: Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol. 41:2351–2355. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lorenz K, Schmitt JP, Schmitteckert EM and Lohse MJ: A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med. 15:75–85. 2009. View Article : Google Scholar : PubMed/NCBI
17	Paul A, Wilson S, Belham CM, Robinson CJ, Scott PH, Gould GW and Plevin R: Stress-activated protein kinases: Activation, regulation and function. Cell Signal. 9:403–410. 1997. View Article : Google Scholar : PubMed/NCBI
18	Sopontammarak S, Aliharoob A, Ocampo C, Arcilla RA, Gupta MP and Gupta M: Mitogen-activated protein kinases (p38 and c-Jun NH2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophy. Cell Biochem Biophys. 43:61–76. 2005. View Article : Google Scholar : PubMed/NCBI
19	Lei B, Chess DJ, Keung W, O'Shea KM, Lopaschuk GD and Stanley WC: Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol. 45:404–410. 2008. View Article : Google Scholar : PubMed/NCBI
20	Vanhaesebroeck B, Guillermet-Guibert J, Graupera M and Bilanges B: The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 11:329–341. 2010. View Article : Google Scholar : PubMed/NCBI
21	Chaanine AH and Hajjar RJ: AKT signalling in the failing heart. Eur J Heart Fail. 13:825–829. 2011. View Article : Google Scholar : PubMed/NCBI
22	Badorff C, Ruetten H, Mueller S, Stahmer M, Gehring D, Jung F, Ihling C, Zeiher AM and Dimmeler S: Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest. 109:373–381. 2002. View Article : Google Scholar : PubMed/NCBI
23	Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, et al: Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 151:117–130. 2000. View Article : Google Scholar : PubMed/NCBI
24	Creemers EE and Pinto YM: Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 89:265–272. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hutchinson KR, Guggilam A, Cismowski MJ, Galantowicz ML, West TA, Stewart JA Jr, Zhang X, Lord KC and Lucchesi PA: Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physio. 111:1778–1788. 2011. View Article : Google Scholar